Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David A. Stamler
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Beta
- -0.03
- Country
- AU
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 5.14
Financials
Revenue
$0.00-100.0%Net Income
$-13.98MEBITDA
$-15.52MFree Cash Flow
$0.00EPS (diluted)
$-0.78Shares Outstanding (diluted)
18.13M+8190.4%Operating Expenses
$15.52MCash & Debt
$37.32MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-22.89M | $-1.32 |
| 2025 | $5.44M | $-12.15M | $-1.14 |
| 2024 | $4.02M | $-19.12M | $-3.12 |
| 2023 | $3.92M | $-13.81M | $-3.42 |
| 2022 | $5.12M | $-12.85M | $-3.18 |
| 2021 | $4.34M | $-15.31M | $-5.40 |
| 2020 | $0.00 | $-10.06M | $-6.48 |
| 2019 | $108.5K | $-11.96M | $-11.64 |
| 2018 | $201.2K | $-8.27M | $-9.30 |
| 2017 | $132.4K | $-7.54M | $-8.46 |
| 2016 | $142.7K | $-7.73M | $-8.70 |
| 2015 | $176.8K | $-5.89M | $-7.02 |
| 2014 | $363.8K | $-13.33M | $-18.66 |
| 2013 | $150.9K | $-7.79M | $-13.80 |
Valuation
ATHEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+4.35%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·1d ago·Positive
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate
View source ↗ - Newsglobenewswire.com·55d ago·Positive
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 – Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential –
View source ↗
Earnings
Thu, Mar 4(in 5 months)
Consensus estimate $-0.03 per share
Typical surprise +18.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 28$-0.05 vs $-0.12beat
- Wed, Feb 25$-0.42 vs $-0.25miss
- Thu, Aug 28$-0.34 vs $-0.56beat
- Fri, Feb 28$-0.57 vs $-0.69beat
- Thu, Aug 29$-0.80 vs $-0.07miss
Estimates and results for ATHE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATHE officers and directors.
- Bought
- $71k
- Sold
- —
3 trades
0 trades
- Marks Peter Ashleybought
- Marks Peter Ashleybought
- Stamler David Allenbought
18 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ATHE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.